INTRODUCTION

Myasthenia gravis is known to occur with thymoma in 10-15% of patients and with other autoimmune diseases, such as hyperthyroidism, polymyositis and systemic lupus erythematosus, rheumatoid arthritis and ulcerative colitis. Nevertheless, autoimmune hepatitis is known to be very rarely associated. Four cases of myasthenia gravis with autoimmune hepatitis have been reported in the world. We recently experienced a case of 30-year-old man with myasthenia gravis associated with thymoma and autoimmune hepatitis. This condition is the first case that has not been reported previously in Korea. We report this rare condition along with a brief review of the literature.

Key Words: Autoimmune hepatitis; Myasthenia gravis; Thymoma

CASE

A 30-year-old male patient was admitted to the Department of Internal Medicine at our hospital for the evaluation and treatment of ptosis of the right eye and blurred vision for 1 month. The patient also experienced fatigue and generalized weakness. He was neither a smoker nor an alcoholic, and had no history of drug abuse, including herbs. His family history was unremarkable. On physical examination, his height was 173 cm, body weight was 63 kg. Body temperature was 36.5°C, pulse rate was 20/min, respiratory rate was 20/min and blood pressure was 120/70 mmHg. He had a chronically ill appearance and the sclera was not icteric. On respiratory and cardiac auscultation, no abnormal sound heard. On abdominal examination, no abnormal tenderness and hepatosplenomegaly were not detected. On neurologic examination, the function of the cranial nerves, including pupillary reflexes of both eyes, was intact and the pathologic reflexes, including the Babinski sign, were not detected. A pathognomonic sign of myasthenia gravis, tendon test, was positive. Hematologic tests showed WBC 3900/mm³, hemoglobin 13.4 g/dL, platelet 139,000/mm³, and blood chemistry showed total bilirubin 1.4 mg/dL, alkaline phosphatase 82 U/L, total protein/albumin 7.3/5.0 g/dL, gamma GT 32 U/L, BUN/creatinine 100.9 mg/dL, LDH 371 U/L, CK 57 U/L.
Na/KCl 145/4.1/106 mmole/L. However, liver enzymes were markedly elevated (AST/ALT 400/777 U/L) and prothrombin time was slightly prolonged (INR 1.35).

Anti-acetylcholine receptor antibody titer was elevated to 3.8 nmole/L (normal < 0.2 nmole/L). Tests of etiologic agents for viral hepatitis were anti-HAV IgM (-), HbsAg (-), HBV-DNA (-), anti-HCV (-), HCV-RNA by PCR method (-), anti-HDV by RIA method (-), HEV (-), anti-CMV IgM (-), and anti-EBV (-). Autoantibody were ANA (+, 1:40, speckled pattern), anti-smooth muscle Ab (-), anti-LKM Ab (-), anti-microsomal Ab (-), anti-mitochondrial Ab (-), anti-dsDNA Ab (-), anti-smooth Ab (-), anti-thyroglobulin Ab (-). Screening tests for Wilson's disease showed normal values, serum copper 99 g/dL and serum ceruloplasmin 20 mg/dL, and Kayser-Fleisher rings were not observed. Alpha 1-antitrypsin was 244 mg/dL and serum choline esterase was 1605 IU/L. These were within normal value. Thyroid function tests showed T3 153 ng/dL, T4 11.1 g/dL, TSH 2.33 IU/mL. The urinalysis was normal. A chest X-ray showed no active parenchymal lung lesion or mass, but the chest CT scan showed 3x4x5 cm-sized low-attenuated homogenous oval shaped mass with sharp margin at the anterior mediastinum. There was no enlargement of lymph node in thoracic cavity. The mass was diagnosed as thymoma, radiologically (Figure 1). Abdominal sonography showed no abnormal findings. His HLA typing was A11, A31, B51, B13, Cw4, Cw6, DR09 and DR12. In the follow-up liver function tests, AST/ALT were elevated to 33/918 and liver biopsy was performed. Biopsy showed distorted lobular architecture and widening of portal tracts by chronic inflammatory cell infiltration with foci of piecemeal necrosis and fibrosis. Thus it was diagnosed as chronic active hepatitis (Figure 2). According to the scoring system of International Autoimmune Hepatitis Group, his pre-treatment score was 14, which is compatible with the probable diagnosis of autoimmune hepatitis. He was treated with prednisone 30 mg/day per oral and 20 days later AST/ALT decreased to 45/73 IU/L and, thereafter, he received thymectomy. On operative fields, solid mass (3x4x5 cm) was identified at the anterior mediastinum. It was encapsulated with yellow gelatin-like material. Histology confirmed that the thymoma was encapsulated, non-invasive and mixed type (Figure 3). After thymectomy, ptosis and blurred vision disappeared. Prednisone was gradually tapered and stopped, but AST/ALT level was elevated up to 239/393 IU/L. Therefore, he was treated again with prednisone, 10 mg/day, and liver function returned to normal value. His post-treatment score was 17, which is compatible with the definite diagnosis of autoimmune hepatitis.

**DISCUSSION**

Myasthenia gravis is an organ-specific autoimmune disease that results from an antibody-mediated assault on the muscle nicotinic acetylcholine receptor at the neuromuscular junction. Thymomas are found in approximately 15% of myasthenia gravis patients and are usually associated with a later age of disease onset. Thymectomy increases the remission rate and improves the clinical course of myasthenia gravis.

About 10% of myasthenia gravis patients are associ-
ated with another autoimmune diseases, such as hyperthyroidism, polymyositis, systemic lupus erythematosus, rheumatoid arthritis, uveitis, collagen, sarcoidosis, pemphigus anemia, but autoimmune hepatitis is very rarely associated.

There is no individual feature that is pathognomonic for autoimmune hepatitis, and its diagnosis requires the confident exclusion of other conditions because the clinical course, treatments and prognosis is different (Table 1). For example, genetic disorders of the liver, including Wilson's disease, hemochromatosis and alpha 1-antitrypsin

Table 1. Differential diagnosis of autoimmune hepatitis

| Diagnostic consideration | Exclusionary studies |
|--------------------------|----------------------|
| Wilson's disease          | ceruloplasmin        |
|                           | urinary copper excretion |
| Hemochromatosis           | serum ferritin        |
|                           | serum iron, transferrin |
| α-antitrypsin deficiency  | hepatic iron stain    |
|                           | hepatic iron index    |
| Chronic hepatitis B       | HbsAg, anti-HBc, HBV-DNA |
| Chronic hepatitis C       | anti-HCV, HCV-RNA     |
| Drug-induced hepatitis    | clinical history      |
|                           | discontinuation of drug |
| Primary biliary cirrhosis | antibodies to ME antigens |
|                           | liver tissue examination |
|                           | hepatic copper stain  |
|                           | unresponsive to steroids |
| Primary sclerosing cholangitis | cholangiography |

Table 2. Clinical criteria for diagnosis of autoimmune hepatitis proposed by the International Autoimmune Hepatitis Group

| Definite autoimmune hepatitis | Probable autoimmune hepatitis |
|-------------------------------|-------------------------------|
| Normal serum l-antitrypsin, copper and ceruloplasmin levels | Abnormal serum copper or ceruloplasmin levels but Wilson's disease excluded |
| Seronegativity of lgM anti-HAV, HBsAg, lgM anti-HBC, and anti-HCV | Anti-HCV may be present but not active true infection |
| Seronegativity for cytomegalovirus and Epstein-Barr virus | Same requirement |
| No parenteral blood exposure | Same requirement |
| Average ethanol ingestion <35 g daily for men and 25 g daily for women | <50 g daily for men and 40 g daily for women |
| No recent use of hepatotoxic drugs | Recent use but active disease after drug withdrawal |
| Any serum aminotransferase abnormality (must exceed alkaline phosphatase elevation) | Same requirement |
| Gamma globulin, IgG, or total globulin level >1.5 times normal | Any elevation acceptable |
| Smooth muscle antibody, anti-nuclear antibody or anti-liver/kidney microsomal antibody > 180 in adults or 120 in children | Titer at least 1:40 in adults and 1:10 in children |
| Liver biopsy examination showing moderate to severe piecemeal necrosis with or without lobular hepatitis or central-portal bridging necrosis | Seronegativity acceptable if other liver related autoantibodies are present |
| No biliary lesions, granulomas, copper deposition, or other features suggesting different diagnosis | Same histologic requirements |
deficiency must be confidently excluded because of different effective therapies or important familial implications. Drug-induced liver disease, especially those associated with the use of alpha-methyldopa, nitrofurantoin and propylthiouracil, must be excluded because discontinuation of the drug cures the disease. Chronic viral infection, especially those related to the hepatitis B virus and hepatitis C virus, must be excluded because antiviral therapy in selected instances may be beneficial. The International Autoimmune Hepatitis Group (IAHG), the Working Party of the World Congress of Gastroenterology (WCC) and the International Association for the Study of the Liver (IASL) proposed the clinical criteria for the definite and probable diagnosis of autoimmune hepatitis (Table 2)\textsuperscript{8}. They emphasize the importance of compatible findings in laboratory profiles and liver histology and the absence of other etiologic factors. Our patient is compatible with definite autoimmune hepatitis by clinical criteria. The IAHG has also proposed a scoring system for the definite and probable diagnosis of autoimmune hepatitis (Table 3)\textsuperscript{8}. It has the theoretic advantages of including all features of the disease in the final diagnosis, balancing diagnostically compatible and incompatible findings in an objective fashion\textsuperscript{7}. Our patient had the corticosteroid pretreatment aggregate scores of 14, thus the probable diagnosis of autoimmune hepatitis was possible, and it increased up to 17 after treatment with steroid, which was compatible with the definite

| Gender | Alcohol |
|--------|---------|
| Female | <25 g/day +2 |

| Alkaline phosphatase-to AST (ratio of elevations above normal) | Concurrent autoimmune disease |
|---------------------------------------------------------------|-----------------------------|
| ≥ 3 | Patient of relative +1 |
| <3 | Histologic findings |

| Gamma globulin or IgG levels above normal | Lobular hepatitis and bridging necrosis +3 |
|------------------------------------------|------------------------------------------|
| >2.0 | Bridging necrosis +2 |
| 1.5-2.0 | Rosettes +1 |
| 1.0-1.5 | Marked/predominantly plasma cell infiltrate +1 |
| <1.0 | Biliary changes -1 |

| ANA, SMA, or anti-LKM1 >180 | Other changes suggestive of different etiology -3 |
|---------------------------|---------------------------------------------|
| 180 | HLA phenotypes |
| 140 | B8-DR3 or DR4 +1 |
| <140 | Treatment responses |

| Antimitochondrial antibody | Complete +2 |
|---------------------------|-------------|
| Positive | Partial 0 |
| Viral markers* | Treatment failure 0 |
| IgM anti-HAV or HBsAg | No response -2 |
| HCV RNA | Relapse +3 |
| Anti-HCV/RIIBA | Diagnostic aggregate scores |
| All negative | Pretreatment |

| Drugs | Treatment responses |
|-------|----------------------|
| Yes | Probable 10-15 |
| No | Definite >17 |

| Blood transfusion | Probable 12-17 |
|------------------|----------------|
| Yes | -2 |
| No | +1 |

AST: Aspartate aminotransferase, ANA: antinuclear antibody, SMA: smooth muscle antibody, anti-LKM1: anti-liver/kidney microsomal 1 antibody, HLA: human leukocyte antigen. From Czaja AJ. Autoimmune hepatitis, Evolving concepts and treatment strategies. Dig Dis Sci 40: 435, 1995
diagnosis of autoimmune hepatitis.

Seronegativity for anti-smooth muscle Ab and anti-nuclear Ab no longer precludes the diagnosis of autoimmune hepatitis\(^8\). The strength of the clinical, laboratory and histologic findings can support the diagnosis even if the unconventional immunoassay systems are unavailable or negative (see Table 2)\(^9\)-\(^10\).

A conceptual framework for the pathogenesis of autoimmune hepatitis is that a genetically predisposed host is exposed to an environmental agent which triggers an autoimmune process directed at liver antigens, causing a progressive necroinflammatory reaction that results in fibrosis and cirrhosis. As in other autoimmune diseases, there are primary associations with the HLA B8, DR3 and DR52a loci. There is also a secondary association with HLA-DR4 in white patients and a primary association with HLA-DR4 in Asians\(^9\)-\(^10\). However, no related HLA locus was detected in our patient. Nowadays, the disease association with specific loci in the HLA-DR region and identified specific amino acid sequences in the light chains of the HLA-DR beta molecules were suggested as more specific markers\(^11\). The susceptibility of the patient to myasthenia gravis and autoimmune hepatitis seems to be related to HLA DR3. There is probably an inter-play of genetic and environmental factors in the occurrence of these diseases\(^2\).

Autoimmune hepatitis generally is responsive to corticosteroid treatment and the remission rate induced by initial therapy is approximately 80%. In general, the prognosis is inversely correlated with the histologic severity of the disease\(^9\). The course of myasthenia gravis is variable. Exacerbations and remissions may occur, but remissions are rarely complete or permanent. Virtually all myasthenic patients can achieve full productive lives with proper therapy, such as anticholinesterases, prednisone, azathioprine and plasmapheresis\(^12\). Prednisone treatment induces remission or significantly improves the disease in more than half of the patients\(^9\). Despite the coexistence of the autoimmune hepatitis and myasthenia gravis, a good response can be obtained with prednisone and thymectomy.

REFERENCES

1. Andrew G, Engel. Disorders of neuromuscular transmission. In: Bennett JC and Plum F, eds. Cecil textbook of medicine. 20th ed. p 2172-2173, Philadelphia: Saunders, 1996
2. Ko KF, Ho T. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 65:492-496, 1998
3. Akon-Segovia D, Gaborin RF, Maldonado JE, Howard FM. Systemic lupus erythematosus following thymectomy for myasthenia gravis: report of 2 cases. Lancet 2:662-665, 1963
4. Fairfax AJ, Doniach D, Wells CE. A membrane-associated autoantibody in a case of myasthenia gravis with chronic hepatitis. Clin Exp Immunol 25:383-388, 1976
5. Kikuchi H, Hayashi N, Nakajima T, Kubo H, Tokuoige K, Kubo S, Yasuo K, Sandou J, Takahashi Y, Yajima M, Someya K, Obata H. A case report of autoimmune hepatitis with myasthenia gravis. Nippon Shokakibyo Gakkai 85:2261-2264, 1988
6. Graus YMF, Baets MHD. Myasthenia gravis: an autoimmune response against the acetylcholine receptor. Immunol Res 12:78-100, 1993
7. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 80:973-994, 1996
8. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 18:998-1005, 1993
9. Czaja AJ. Diagnosis, prognosis, and treatment of classical autoimmune chronic active hepatitis. In: Krawitt EL, Wiesner RH, eds. Autoimmune liver disease. p. 143, New York, Raven Press, 1991
10. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104: 1755-1761, 1993
11. Doherty DG, Donalson PT, Underhill JA, Farmat JM, Duthie A, Giorgina MV, McFarlane KG, Johnson PJ, Eddeston ALWF, Mkowat AP, Williams R. Allelic sequence variation in the HLA class I genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609-615, 1994
12. Danchman DB. Myasthenia gravis and other disease of the neuromuscular junction. In : Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. Harrison's principles of internal medicine. 14th ed. Vol. 2, p.2469-2472, New York; McGraw-Hill, 1998